Infigratinib is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. Infigratinib, is an anti-cancer medication used to treat cholangiocarcinoma (bile duct cancer).<\/p>\n
Infigratinib is a kinase inhibitor targeting the fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3 It was designated an orphan drug by the US Food and Drug Administration (FDA) in 2019, and it was approved for medical use in the United States in May 2021.<\/p>\n
Truseltiq (infigratinib capsules) for oral use Initial U.S. Approval: 2021<\/strong> Note:<\/strong> Truseltiq (infigratinib) is a prescription medicine used to treat previously-treated locally advanced or metastatic bile duct cancer (cholangiocarcinoma).<\/p>\n Disease Indications-Bile Duct Cancer If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cinfigratinib capsules” based on the information you provide.<\/p>\n
\nIf infigratinib capsules are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN.<\/strong> For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/p>\n","protected":false},"excerpt":{"rendered":"Generic Name: Infigratinib Capsules
\nInfigratinib Capsules is used to treat a certain type of cholangiocarcinoma (bile duct cancer).<\/h2>\nFacts about infigratinib capsules<\/h4>\n
\nManufacturer-QED Therapeutics
\nUsage-Oral Capsules: 25 mg and 100 mg
\nMedicine Approved By-Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n